Welcome to the IPE Reference Hub. This site uses cookies. Read our policy.

Columbia Threadneedle Investments

2025 Top 500 ranking: 44

A bitter pill: what tariffs could mean for pharmaceutical firms and the wider healthcare industry

A bitter pill- what tariffs could mean for pharmaceutical firms and the wider healthcare industry

The US government’s proposal to impose tariffs on pharmaceutical imports has ignited a complex debate, intertwining economic, healthcare, and geopolitical considerations. While the initiative aims to bolster domestic manufacturing and reduce reliance on foreign supply chains, it also raises concerns about drug affordability and availability, and has broader implications for ...

This is premium content

You are not logged in, Sign in or register to request access. 
Please note: If you had prior access to this content you may need to sign in again.

Asset Owners

If you are an institutional investor you are eligable for free access to all premium content.

REGISTER NOW

Asset Managers

Asset managers with enhanced profiles are eligable for full access.

Please sign-in using your work email address or:

REGISTER NOW